PIK3CA and ovarian carcinoma: The combination of the pan-PI3K inhibitor LY294002 with cisplatin effectively inhibits the proliferation and migration of ovarian cancer cells by downregulating the expression of Matrix Metalloproteinase-2 (MMP-2), TIMP1, and TIMP2 (Ediriweera et al., 2019).